Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Randomized, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneously Administered Efalizumab Used in Combination With Topical Psoriasis Therapies for Prolonged Maintenance Treatment

NCT00096980 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT00096980
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00096980 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Randomized, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneously Administered Efalizumab Used in Combination With Topical Psoriasis Therapies for Prolonged Maintenance Treatment
Lead sponsor
Genentech, Inc.
Phase
Phase 4
Overall status
Completed
Start date
February 28, 2001
Completion date
May 31, 2004
Enrollment
300
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis